Vise Technologies Inc. Makes New Investment in Medpace Holdings, Inc. $MEDP

Vise Technologies Inc. acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,149 shares of the company’s stock, valued at approximately $608,000.

Other institutional investors also recently modified their holdings of the company. California State Teachers Retirement System grew its holdings in shares of Medpace by 22.1% during the first quarter. California State Teachers Retirement System now owns 26,042 shares of the company’s stock worth $12,505,000 after purchasing an additional 4,719 shares during the last quarter. Focus Partners Advisor Solutions LLC bought a new position in shares of Medpace in the second quarter valued at about $1,685,000. BlackRock Inc. bought a new position in shares of Medpace in the second quarter valued at about $1,323,047,000. Local Pensions Partnership Investment Ltd lifted its position in Medpace by 10.5% during the 2nd quarter. Local Pensions Partnership Investment Ltd now owns 42,000 shares of the company’s stock worth $22,265,000 after buying an additional 4,000 shares in the last quarter. Finally, Cerity Partners LLC lifted its position in Medpace by 41.0% during the 4th quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock worth $45,478,000 after buying an additional 23,530 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on MEDP shares. Royal Bank Of Canada raised their price objective on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $535.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Mizuho raised their price target on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Finally, Leerink Partners set a $620.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, Medpace has a consensus rating of “Hold” and an average price target of $584.18.

Insiders Place Their Bets

In other news, Director Cornelius P. Mccarthy III sold 1,140 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $605.37, for a total value of $690,121.80. Following the completion of the sale, the director directly owned 12,275 shares of the company’s stock, valued at $7,430,916.75. This represents a 8.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Brian T. Carley sold 5,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the completion of the sale, the director owned 27,825 shares in the company, valued at $16,935,129.75. This represents a 15.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 125,661 shares of company stock valued at $73,854,945 in the last ninety days. 20.50% of the stock is currently owned by insiders.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $620.03 on Tuesday. The stock has a market cap of $17.31 billion, a price-to-earnings ratio of 36.34, a P/E/G ratio of 2.77 and a beta of 1.15. The company has a 50 day moving average of $553.21 and a 200-day moving average of $492.40. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same period last year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.